Prenumeration
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
OncoZenge has signed a revised agreement with Molteni Farmaceutici, whereby Molteni formally assumes responsibility for volume manufacturing of BupiZenge for the European market. According to the company, neither the remaining allocation of responsibilities nor commercial terms, including milestones, are affected. The amended agreement strengthens OncoZenge's asset-light strategy and shifts a large part of the operational responsibility for the supply chain and costs to the partner ahead of continued scale-up during 2026.
Read the full article at biostock.se:
OncoZenge and Molteni expand partnership for BupiZenge
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/